Brain and Cognition Discovery Foundation
Data updated
Canada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
Foundations & Philanthropy Snapshot
Psychedelic-Specific FoundationsClassification
Private Foundation
Geography
National
Coverage
Coverage not set
Last Verified
Apr 10, 2026
Funding Focus Areas
Support Types
Verification
Verified
Psychedelic Focus
Explicit Psychedelic Focus
Engagement Status
Active
Recorded Funding Activities
Canadian Rapid Treatment Centre of Excellence / University of Toronto (Joshua Rosenblat, Roger McIntyre)
Mar 8, 2024
program-funding - Sponsored Phase 2 randomized clinical trial of repeated-dose psilocybin-assisted psychotherapy for treatment-resistant depression (NCT05029466) - undisclosed
BCDF (founded 2015 by Dr Roger McIntyre) was study sponsor; Usona supplied synthetic psilocybin at no cost and Braxia Scientific provided clinic facilities.
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybinUniversity of Toronto / mood-disorders research team (McIntyre, Rosenblat et al.)
Jan 1, 2025
program-funding - Psilocybin-assisted psychotherapy study for treatment-resistant depression in bipolar II disorder - undisclosed
BCDF-affiliated investigators; continuation of the foundation's psilocybin research programme.
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder (Psychedelic Medicine)Research journey
Built from the 3 trials Brain and Cognition Discovery Foundation has sponsored, placed at the date each one started.
Quick Facts
- Type
- Non-Profit
- HQ
- Canada
- Website
- Visit
Sponsored Trials
3Psilocybin for Treatment-Resistant Depression
- Start Date
- Compounds
- Psilocybin
Pharmacogenetics Associated With IV Ketamine
- Start Date
Chart Review of Patients Undergoing Ketamine Infusions
- Start Date
- Compounds
- Ketamine
Where this pipeline sits in the field
Brain and Cognition Discovery Foundation runs late-stage trials that Blossom ranks by how soon a catalyst is expected, alongside every other Phase 2 and Phase 3 study in the field.
Recent activity
- CompletedChart Review of Patients Undergoing Ketamine Infusions (NCT04209296, ketamine)
- CompletedPsilocybin for Treatment-Resistant Depression (NCT05029466, psilocybin)
- StartedPsilocybin for Treatment-Resistant Depression (NCT05029466, psilocybin)
- CompletedPharmacogenetics Associated With IV Ketamine (NCT04695405)
- StartedPharmacogenetics Associated With IV Ketamine (NCT04695405)
- StartedChart Review of Patients Undergoing Ketamine Infusions (NCT04209296, ketamine)